Archive for the ‘Treatment’ Category

ACTION: Retract Deplorable Lyme Disease CME

https://www.change.org/p/the-us-senate-calling-for-a-congressional-investigation-of-the-cdc-idsa-and-aldf/u/34006713?

Medscape Now! Interprofessional Care of Post-Treatment Lyme Disease Syndrome

Carl Tuttle
Hudson, NH, United States
Oct 25, 2025

What was deceitfully established here in the US has been propagated worldwide as signatures for this petition are coming in from 21 countries!

Let’s put our numbers to work. Consider writing an email to Adrian Duncan of Medscape/WebMD referencing this Update and demand a retraction of this deplorable and misleading CME directed to the medical community. 

Change.org Petition Update (106,796 Signatures)
https://www.change.org/p/the-us-senate-calling-for-a-congressional-investigation-of-the-cdc-idsa-and-aldf/u/34006713

Medscape Now! Interprofessional Care of Post-Treatment Lyme Disease Syndrome

Adrian Duncan, Group Vice President
Global Head of Education & Medical Affairs

aduncan@webmd.net

———- Original Message ———-
From: CARL TUTTLE <runagain@comcast.net>
To: “aduncan@webmd.net” <aduncan@webmd.net>
Cc: “cme@medscape.net” <cme@medscape.net>, “caitlin@medlitera.com” <caitlin@medlitera.com>, “naseem@medlitera.com” <naseem@medlitera.com>, “michelle@medlitera.com” <michelle@medlitera.com>

Date: 10/24/2025 12:42 PM EDT
Subject: Medscape Now! Understanding the Latest Evidence and Best Practices for Interprofessional Care of Post-Treatment Lyme Disease Syndrome

Medscape Now! Understanding the Latest Evidence and Best Practices for Interprofessional Care of Post-Treatment Lyme Disease Syndrome
https://www.medscape.org/viewarticle/medscape-now-understanding-latest-evidence-and-best-2025a1000rrr
CME Author: Naseem Bazargan, MPH     Developed with AI assistance.

Excerpt:

State of the Evidence

“To date, our understanding of the pathophysiology of Lyme IACI remains limited,[4] with little to no evidence supporting chronic Borrelia infection as the underlying cause.”

Adrian Duncan, Group Vice President
Global Head of Education & Medical Affairs

Dear Mr. Duncan,

In reference to the Medscape article written by Naseem Bazargan, I asked Google’s Gemini AI the following questions:

The latest Medscape CME education claiming to be developed with AI assistance, appears to have omitted the following references:

  • 2018 Middelveen study; “Persistent Borrelia Infection in Patients with Ongoing Symptoms of Lyme Disease” identifying twelve patients who were culture positive after antibiotic treatment. Some of these patients had taken as many as eleven different types of antibiotics. Also missing is the NIH funded Embers studies of persistent Bb infection in monkeys and mice. And the Sapi study: “The Long-Term Persistence of Borrelia burgdorferi Antigens and DNA in the Tissues of a Patient with Lyme Disease”  Here is the positive culture report from the CDC at Fort Collins Colorado and the chronic Lyme autopsy results from the patient in the Sapi study: Page 1, 2, 3, 4, 5, 6, 7. The destructive nature of Borrelia is evident in the patient’s liver (nutmeg liver), kidneys, heart, lungs and brain. The patient died after the insurer refused additional IV antibiotic therapy.
  • Additional reference from 1990: “Chronic neurologic manifestations of Lyme disease” Dr. Allen Steere
  • In fact, there appears to be 700 references identifying persistent infection. 

Question: So, is AI participating in the collusion to suppress evidence of antibiotic resistance or chronic Lyme disease? And what about the other 700 references identifying persistent infection?

Mr. Duncan…  I will spare you the lengthy discourse and get right to the point.

Questions to AI:

1. Does a chronic relapsing seronegative disease fit the vaccine model?

AI Response:

A chronic, relapsing, seronegative disease does not fit the traditional vaccine model, which is primarily designed to prevent initial infections. The characteristics you describe present significant scientific and commercial challenges for vaccine developers.

2. Since you agreed that a chronic, relapsing, seronegative disease does not fit the traditional vaccine model this in and of itself would be the motivation to conceal any and all evidence of persistent infection wouldn’t you agree? This so-called debate is not a debate at all and deserves a criminal investigation. Who would be a suitable candidate to approach for a legal case?

AI Response: Allegations of medical fraud are typically handled as civil matters, but they can become criminal if there is evidence of gross negligence, recklessness, or intent to deceive, especially for financial gain.

Mr. Duncan,

Thirty-four years ago Dr. Allen Steere identified chronic Lyme disease which should have set off a red flag prompting an immediate search for better antimicrobials but then did a 180° as he became principal investigator (PI) of the Phase 3 clinical trial for the first Lyme disease vaccine. So all the eggs were put into the vaccine basket while a campaign was orchestrated to discredit the sick and disabled patient population along with the courageous clinicians attempting to help these patients. Apparently, a chronic relapsing seronegative disease did not fit the business model of patent royalties, vaccine development and pharmaceutical profits. This set the stage for long-term treatment denial and unimaginable pain and suffering around the world. It has been ongoing for over three decades now and the latest CME from Medscape is propagating this travesty.

Lyme disease has been grossly mishandled by our public health officials for the sake of a vaccine. A false public health narrative was enforced and any clinician who did not follow that narrative risked losing their license to practice medicine as seen in the documentary: Under our Skin. (please watch the 5min trailer)

I want to make this crystal clear; suppressing evidence of antibiotic resistance is not collaboration, it is collusion. Will you turn a blind eye to the facts/evidence I have presented?

A response to this inquiry is requested.

Respectfully submitted,

Carl Tuttle
Independent Researcher
Hudson, NH USA

Additional references:

Evidence Of Persistence Of Lyme Disease In Humans
https://www.lymedisease.org/lyme-basics/resources/evidence-of-persistence-lyme-disease-in-humans/

Go here to sign Tuttle’s petition:  https://c.org/sffxsgXrdJ

________________

For more:

Category:

Activism, Lyme, research, Treatment

Research Catching Up to Post-Acute COVID-19 ‘Vaccination’ Syndrome

https://imahealth.substack.com/p/from-fringe-to-focus-how-research?

From Fringe to Focus: How Research Is Catching Up to Post-Acute COVID-19 Vaccination Syndrome (PACVS)

PACVS (Post-Acute COVID Vaccine Syndrome) is real, and the science is finally opening up. Months ago, IMA researchers broke ground. Now, another team is validating what patients have known all along.

Independent Medical Alliance
Oct 22, 2025
Research catching up to PACVS

Those suffering from Post-Acute COVID-19 Vaccination Syndrome (PACVS) face not only debilitating symptoms but also institutional resistance to recognition, diagnosis, and care. Despite these barriers, researchers are beginning to shed light on this under-recognized condition. Those who follow IMA know we’ve been working in this space for years—seeing our peers in the research community finally open up is more than encouraging.

A recent publication by Yong et al. in Reviews in Medical Virology offers one of the most comprehensive summaries to date on PACVS (which they refer to as Post-COVID-19 Vaccination Syndrome, or PCVS). Their team, spanning 25 institutions, reviewed existing scientific literature and highlighted several important areas of progress:

*See references in https://onlinelibrary.wiley.com/doi/epdf/10.1002/rmv.70070

Key Takeaways from the Review:

Terminology

The review outlines the evolving language around this condition—from “Long Vax” to “post-vac syndrome.” At the Independent Medical Alliance, we’ve adopted Post-Acute COVID-19 Vaccination Syndrome (PACVS) as our standard terminology to reflect both the temporal and mechanistic distinctions from Long COVID.

Symptom Clusters

The article identifies hallmark symptoms that will be familiar to both clinicians and patients: fatigue, cognitive dysfunction (brain fog), and paresthesia.

*This figure for post-COVID-19 syndrome is reproduced under an Attribution-NonCommercial 4.0 International license

The image above is adapted from an earlier study on “post-COVID-19 syndrome” (long COVID). The more recent article expands on this by introducing additional system categories: autonomic, visual, auditory, gustatory**, and multi-system syndromes that highlight a broader range of physiological effects.

It introduces new symptoms, including

  • paresthesia
  • neuropathy
  • tremors
  • orthostatic hypotension
  • fluctuating blood pressure or heart rate
  • heat or cold intolerance
  • vision problems
  • tinnitus
  • taste dysfunction
  • urticaria
  • exercise intolerance.

It also adds a new section on multi-system and immune-mediated conditions such as POTS, SFN, ME/CFS, myocarditis, VITT, and ITP, framing the syndrome as a more complex, vaccine-specific condition with autonomic and immune involvement beyond the generalized symptoms in the second image.

Proposed Mechanisms

The authors explore two leading hypotheses for PACVS: one centering on spike protein–induced tissue damage and another on dysregulated immune responses. While not mutually exclusive, both warrant deeper investigation.

Treatment Landscape

Though research is still early, the paper compiles a useful snapshot of current treatment strategies—ranging from manual therapies (e.g., compression garments, vestibular rehab) to pharmaceuticals (SNRIs, modafinil) and nutraceuticals (melatonin, NADH, acetyl-l-carnitine).

📣 Call for Papers: PACVS Special Edition

Our team at the Independent Medical Alliance has made PACVS research a central focus. Now, we’re inviting submissions for a special edition of the Journal of Independent Medicine dedicated to this emerging condition. If you’re studying spike injury, vaccine-related syndromes, or chronic post-injection effects, we encourage you to submit your work or learn more here before the submission deadline of December 31, 2025.

The Yong et al. review is a welcome contribution to the growing PACVS landscape, but much more research is urgently needed. Our team recently published a complementary case series on PACVS mechanisms and treatment hypotheses, available here:

👉 Read the study in Heliyon
👉 Read the summary at IMAHealth.org

Together, let’s build the evidence base for the patients still waiting to be heard.

🔬 Explore Our Independent Research Hub

From vaccine safety and cancer care to post-COVID protocols and chronic disease, our research team and Senior Fellows are producing science that challenges the status quo. The Research Hub is where you’ll find all our published studies, reviews, and groundbreaking monographs, all organized, accessible, and free to the public.

For more:

Category:

research, Treatment, vaccines

Bioengineering Without Boundaries: Why Lyme Disease Belongs in the GMO Debacle

https://gmoscience.org/2025/10/20/bioengineering-without-boundaries-why-lyme-disease-belongs-in-the-gmo-debacle/

Bioengineering Without Boundaries: Why Lyme Disease Belongs in the GMO Debacle

Michelle Perro, MD
Published: October 20, 2025

Lyme disease is not simply an infection.  It is a lens into the consequences of manipulating biology without accountability. As we confront the obfuscated crisis of Lyme and other chronic infections, it becomes evident that bioengineering in pathogens and genetic engineering in food are part of the same continuum of unregulated biotechnology. Both alter life’s blueprints, both evade oversight, and both are creating a legacy of ecological and human suffering.

In her groundbreaking book, Bitten: The Secret History of Lyme Disease and Biological Weapons, science journalist Kris Newby details how US biowarfare research programs, including work at the Rocky Mountain Laboratories in Hamilton, Montana, experimented with spirochetes to alter virulence and transmission. The intention of these manipulations, although unclear, likely spawned Borrelia burgdorferi, the stealth pathogen now linked to millions of chronic infections worldwide. The same recombinant DNA methods used in agricultural GMOs were being applied in microbial genetics at the time.

“When we manipulate genes for profit or power, the consequences ripple through ecosystems, our children, and future generations.”

Lyme rarely acts alone. It often coexists with Bartonella, Babesia, Ehrlichia, Mycoplasma, Rickettsiae, and viruses such as Powassan, all of which exacerbate inflammation and neuroimmune dysfunction. These infections disrupt the immune system through biofilm formation, cytokine storms, and molecular mimicry, while simultaneously impairing gut barrier integrity; a condition known as ‘leaky gut.’ This state of immune chaos parallels the chronic inflammation seen in individuals exposed to genetically engineered foods and glyphosate residues.

Despite their shared roots in biotechnology, genetically modified foods and engineered pathogens are regulated separately by the USDA, EPA, FDA, NIH, and DOD, none of which coordinate holistic biosafety. This fragmented oversight allows both agricultural and biomedical engineering to advance without unified accountability. The same regulatory capture that shields agri-tech corporations has also protected infectious disease gatekeepers, such as the Infectious Disease Society of America (IDSA), whose restrictive guidelines have left millions of chronic Lyme patients untreated.

Just as the FDA dismisses independent research on GMO toxicity, the IDSA dismisses clinicians and patients suffering from persistent Lyme. Both systems denied chronic exposure or chronic infection, labelled dissenting experts as “fringe,” protecting corporate and institutional interests over public health.  The pattern created is systemic and taken directly from the GMO playbook: create complexity, deny chronicity, and suppress those questioning the government/corporate narrative.

Lyme Mythology

Lyme Disease is the modern plague that never shouldn’t have been. It is now one of the fastest-growing infectious diseases in the United States, with the CDC estimating up to 3 million cases annually when underreporting is considered.

Although black-legged ticks (Ixodes scapularis and I. pacificus) are the best-known carriers, Borrelia DNA has been detected in a variety of other insects, suggesting other forms of transmission.  This fact is little known in mainstream medicine and leaves those with Lyme disease unclear as to how they were infected when consulting with their physicians who just believe that the tick is the only vector of Lyme.

The Multi-Vector Reality: Beyond the Tick

The following graph demonstrates that there are many other potential vectors of Lyme disease which should increase our awareness when facing those with multi- system complaints and health challenges.

Insect Evidence of BorreliaDNA Proven Transmission to Humans Comments
Ticks (Ixodes scapularis, I. pacificus) Strong Yes Primary vector
Mosquitoes (Aedes, Culex) Moderate No Possible mechanical transmission
Horseflies / Deer flies Moderate No Possible mechanical role
Fleas  Detected No Reservoir role in pets/rodents
Mites Rare No Wildlife vector potential
Lice (Pediculus humanus) Different Borrelia) Yes (B. recurrentis, relapsing fever) Demonstrates Borrelia versatility

Sources: Schotthoefer & Frost, 2015; Franke et al., 2020; Eisen et al., 2017; Jaenson et al., 2019.

Integrative Framework

Healing requires more than antibiotics or symptom management. It demands restoration of biological integrity. Integrative and terrain-based approaches rebuild the immune system through microbial, nutritional, and energetic balance.

The gut-immune axis is central to Lyme’s chronicity. Dysbiosis from antibiotics, poor diet, and/or environmental toxins (e.g., glyphosate, heavy metals) compromises the gut-associated lymphoid tissue (GALT).  Over 70% of immune function resides in the gut creating conditions where infections persist and autoimmunity originates.

Supporting terrain integrity is essential though the use of an organic regenerative diet with strict avoidance of glyphosate-contaminated foods (which destroy beneficial gut flora).  Additionally, a whole foods based diet composed of increased polyphenols, flavonoids, healthy fats, and fiber are paramount to healing.

An integrative approach is necessary when helping those with Lyme disease and treatments stem from a multimodal tool box with suggestions outlined in article (See top link).

_______________

**Comment**

One of the best articles I’ve read in a spell.  

My only qualm is with the treatment and transmission info. The antibiotics listed are not the only ones that work and their usage presented is not savvy enough.  Please see:   https://madisonarealymesupportgroup.com/2016/02/13/lyme-disease-treatment/

Lyme literate doctors (LLMDs) have learned to track symptoms and then use treatment that works on given symptoms (that change).  This requires different drugs.  Also, once you beat back Lyme enough, it is quite normal for coinfections to become evident.  These also require different drugs.  Further, dosage matters.  Then, there’s the issue of pulsing and cycling – both techniques that experienced LLMDs use – precisely due to needing a judicious approach since treatment is often protracted.  Throwing antibiotics at this indiscriminately is unwise.

Treatment must be fluid to adapt to the ever changing symptoms.

Also, besides congenital transmission, sexual transmission is highly likely:

Category:

diet and nutrition, Gut Health, Herbs, Lyme, Ticks, Transmission, Treatment

SOT Part 2

https://www.lymedisease.org/sot-for-lyme-part-two/

Targeting Lyme at the genetic level: SOT’s emerging role

This is Part Two of a series on Supportive Oligonucleotide Therapy (SOT),  a form of antisense oligonucleotide therapy. SOT is a personalized, gene-silencing treatment designed to disrupt pathogens like Lyme disease. Read Part One here.

10/8/25

By Maria Marian, ND, MSE

The idea of silencing genes to weaken pathogens may sound futuristic, but antisense oligonucleotide therapies have already proven themselves in medicine.

Cancer research: Multiple antisense drugs have been studied in oncology to block genes that promote tumor growth and survival (e.g., Bcl-2, EGFR). While not all succeeded in trials, these studies helped refine delivery methods and safety monitoring【PMID: 19164450】.

FDA approval for infection: In 1998, fomivirsen (Vitravene) became the first antisense drug approved for human use, targeting CMV retinitis in immunocompromised patients【PMID: 9815174】. This milestone showed that gene silencing could work safely against viruses in humans.

Emerging infectious disease applications:

  • Laboratory studies demonstrate antisense oligonucleotides can inhibit replication of HSV, EBV, hepatitis viruses, and influenza【PMID: 19920191】.
  • In Lyme disease, small clinical series using SOT have reported significant reductions in Borrelia burgdorferi DNA copy numbers in blood following one or two infusions, as measured by PCR. Viral infections like EBV and HSV may require more sessions to achieve measurable results.

Although the published data are limited, these results are encouraging for patients who have exhausted conventional treatment options.

The Patient Experience

From a patient’s perspective, SOT is different from antibiotics, antivirals, or even most integrative therapies.

  • One infusion, long effect: Instead of daily or weekly medication, SOT is given as a single intravenous infusion, yet its activity can last up to six months.
  • Gradual improvement: Because the therapy slowly reduces pathogen replication rather than rapidly killing organisms, many patients notice changes gradually over weeks to months.
  • Reported benefits: Improvements may include reduced fatigue, better cognitive clarity, less pain, and fewer flares of viral reactivation.
  • Side effects: Most reported side effects are mild—such as temporary fatigue, flu-like symptoms, or localized reactions during infusion. Serious side effects appear rare in current reports.

That said, responses vary. Some patients may need multiple SOT cycles for sustained benefit, and others may not notice dramatic changes. As with all therapies, individual outcomes depend on many factors, including immune status, co-infections, and overall health.

Benefits and Strengths of SOT

Patients and clinicians exploring SOT often highlight its unique advantages:

  • Precision: Targets one critical sequence of the pathogen’s genome with minimal off-target effects.
  • Immune-system independent: Works even when immunity is suppressed or exhausted.
  • Continuous action: Active day and night for months, unlike short-lived antibiotics or antivirals.
  • Compatibility: Can be combined with integrative approaches (herbal protocols, detoxification, nutritional support) for a systems-based strategy.

Limitations and Open Questions

Despite its promise, SOT is not a silver bullet. Important limitations remain:

  • Limited clinical research: Most studies so far are pilot projects or case series, not large randomized controlled trials.
  • Not FDA-approved for Lyme or herpes viruses: Currently, its approved infectious disease application (fomivirsen for CMV) is historical. Use for Lyme, EBV, or HSV is off-label/experimental.
  • Cost: Treatments are highly individualized and can be expensive, often not covered by insurance.
  • Unknowns in long-term outcomes: While short-term safety looks good, more research is needed to assess durability of remission and long-term effects.

For these reasons, patients considering SOT should do so under the guidance of a clinician familiar with both its potential and its uncertainties.

Where Does SOT Fit in Chronic Lyme Care?

SOT should be thought of as a potential adjunctive therapy—not a replacement for all other treatments. In chronic Lyme and co-infections, successful treatment usually requires a layered approach, addressing:

  • Microbial burden (Borrelia, Bartonella, Babesia, viruses, parasites)
  • Immune regulation
  • Detoxification and environmental exposures (mold, metals, chemicals)
  • Mitochondrial and hormonal health
  • Lifestyle and resilience factors

Within that framework, SOT may serve as a targeted tool to reduce microbial load when conventional antimicrobials or integrative protocols have plateaued.

The Future of Gene-Silencing Therapies

The broader field of RNA-based medicine is expanding at remarkable speed. In recent years, the FDA has approved multiple oligonucleotide drugs for rare genetic diseases, including:

  • Nusinersen (Spinraza): spinal muscular atrophy【PMID: 29191460】
  • Eteplirsen: Duchenne muscular dystrophy
  • Patisiran: hereditary transthyretin amyloidosis

These approvals show that oligonucleotide therapies can be safe, effective, and commercially viable. As technology advances, it is likely we will see more robust clinical trials for antisense therapies in infectious diseases, improved delivery systems that increase effectiveness and reduce costs, and expanded targets, not only for microbes but also for the inflammatory pathways they trigger.

For the Lyme community, this represents a hopeful horizon: a class of therapies designed with molecular precision to address infections that often resist conventional treatment.

Final Thoughts

Supportive Oligonucleotide Therapy is an exciting example of how genetic medicine is moving from the laboratory into clinical care. While not a cure-all, and not yet backed by large-scale Lyme disease trials, it offers a promising option for patients whose infections have proven stubborn to standard therapies.

As with all emerging treatments, the best approach is a balance of hope and caution: hope that this new tool may bring relief, and caution in recognizing the need for further research and informed decision-making.

For patients and families dealing with the daily challenges of chronic Lyme and viral co-infections, SOT reflects a broader truth in medicine today—sometimes the way forward is not more of the same, but something entirely new.

Click here for Part 1:  SOT therapy for Lyme is experimental, expensive—and full of potential

Maria Marian, ND, MSE, is a naturopathic physician at Jyzen Wellness in Mill Valley, California. In addition to her Doctorate of Naturopathic Medicine, she holds both a Bachelor and Master of Science in Chemical Engineering. She specializes in complex chronic illness, Lyme disease, and integrative approaches to immune dysfunction. Follow her on Instagram: @dr.marian.nd

References
  1. Perry CM, Balfour JA. Fomivirsen. Drugs. 1999;57(3):375–380. PMID: 10080450.
  2. Crooke ST. Antisense Drug Technology: Principles, Strategies, and Applications. CRC Press; 2008.
  3. Stein CA, Castanotto D. FDA-Approved Oligonucleotide Therapies in 2017. Mol Ther. 2017;25(5):1069–1075. PMID: 28457632.
  4. Kole R, Krainer AR, Altman S. RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov. 2012;11(2):125–140. PMID: 22262067.
  5. Khorkova O, Wahlestedt C. Oligonucleotide therapies for CNS disorders. Neurotherapeutics. 2017;14(4):827–840. PMID: 29191460.
  6. Stein CA, Hansen JB, Lai J, et al. Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides. Nucleic Acids Res. 2010;38(1):e3. PMID: 19850725.

Category:

Lyme, Treatment

Ivermectin’s Accidental Breakthrough: Parkinson’s & Alzheimer’s

https://choiceclips.whatfinger.com/2025/10/11/ivermectins-accidental-breakthrough-a-lifeline-for-parkinsons-and-alzheimers-sufferers/

Ivermectin’s Accidental Breakthrough: A Lifeline for Parkinson’s and Alzheimer’s Sufferers

A stunning revelation from the front lines of medicine. Dr. William Makis is reporting unprecedented success using ivermectin for two of our most devastating neurological conditions: Parkinson’s and Alzheimer’s disease. His accidental discovery is yielding results that defy conventional expectations. For Parkinson’s, high-dose ivermectin (60-72mg) is facilitating remarkable recoveries. Patients on maximum standard treatments, once barely mobile, are now experiencing dramatic improvements in movement and symptoms. One such patient, after a few weeks of treatment, returned to playing golf—an activity lost for years. The outcomes in Alzheimer’s are even more profound.

Dr. Makis details how family members, following his protocol of low-dose ivermectin (12-24mg for a few days), are witnessing what can only be described as medical miracles. Loved ones who had not recognized family members for years are suddenly reconnecting. Memories are flooding back; cognitive abilities are being restored. In one extraordinary case, a patient was taken off hospice after their condition improved so drastically. The stories are heart-rending: “My grandma’s back.” Families are reclaiming precious time with loved ones they felt they had lost forever. All from a few pills of a medication with a well-established safety profile.

Dr. Makis challenges the medical establishment, noting that supportive preclinical research on ivermectin and Alzheimer’s appears to have been scrubbed from mainstream search engines, a silent testament to the battle over this repurposed drug. He urges the public to look at the evidence he shares on his platforms. The potential for a safe, accessible, and effective treatment for these neurodegenerative scourges is too significant to ignore.

(See link for article, video, dosages, and links to testimonials)

______________

For more on Parkinson’s:

Alzheimer’s:

Ivermectin:

Category:

Activism, Alzheimer's, Treatment